B&L signs agreements with Pfizer and Santen

Article

Pfizer and Bausch & Lomb are to co-promote their prescription eye drugs in the United States, allowing both companies to increase significantly the support for the products, according to a joint statement released by the companies.

Pfizer and Bausch & Lomb are to co-promote their prescription eye drugs in the United States, allowing both companies to increase significantly the support for the products, according to a joint statement released by the companies.

The five-year agreement involves Pfizer's glaucoma drug, latanoprost (Xalatan), and three Bausch & Lomb products: loteprednol etabonate ophthalmic suspension 0.2% for conjunctivitis (Alrex); loteprednol etabonate ophthalmic suspension 0.5% for inflammatory conditions (Lotemax); and loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (Zylet), which is a combined anti-inflammatory and anti-infective agent.

Bausch & Lomb's besifloxacin, an anti-infective eye drop under review by the FDA, is also included in the deal. Pfizer will continue to maintain three mid-stage ophthalmic development programs in its own pipeline.

Under the new agreement, the sales forces from both companies will promote Xalatan, Alrex, Lotemax, Zylet and, pending FDA approval (expected by B&L sometime this year), besifloxacin.

"Working in collaboration, our US sales organizations will now represent one of the broadest product offerings in the US ophthalmic market," said Flemming Ornskov, global president of pharmaceuticals at Bausch & Lomb.

In a separate agreement, Bausch & Lomb has also entered into a licensing agreement with Santen Pharmaceuticals and has obtained the rights to Santen's hydrophobic acrylic polymers. B & L will use these polymers to commercialize new intraocular lenses (IOLs) for sale worldwide, with the exception of Japan.

Financial terms of the deals have not been disclosed.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.